Rationale for Treatment With Momelotinib in Patients With MF
November 22nd 2023Momelotinib, a recently approved treatment for myelofibrosis, targets multiple pathways,and offers a promising approach to improve anemia, especially in patients who did not respond optimally to previous JAK inhibitors.
Watch
Hussein Tawbi, MD, PhD, explains that for BRAF-mutated metastatic melanoma, treatment options include checkpoint inhibitors, single-agent and combination IO therapies, and BRAF and MEK inhibitor combinations, offering varying response rates and progression-free survival periods.
Watch
When to Initiate Therapy in Patients With MF
November 22nd 2023Dr Anthony Hunter explains that the decision to initiate therapy in patients with myelofibrosis is individualized, considering factors like symptoms and risk stratification; early treatment with JAK inhibitors is crucial for symptom control, but allogeneic stem cell transplant remains the only potential curative therapy, particularly for higher-risk patients.
Watch
DuMontier Discusses Frailty in Newly Diagnosed Multiple Myeloma
November 18th 2023Clark DuMontier, MD, discusses the main takeaways from his presentation on treatment intensity and frailty in newly diagnosed patients with multiple myeloma given at the 20th International Myeloma Society Annual Meeting.
Watch
Clinical Experiences With Momelotinib for Patients With Myelofibrosis
November 17th 2023Dr Abdulraheem Yacoub discusses experience with the JAK inhibitor momelotinib in patients with myelofibrosis, noting robust efficacy in clinical trials for spleen volume reduction, symptom improvement, and anemia benefit, but explains that its utility in first-line versus second-line settings is still being determined.
Watch
Currently Available Treatment Options for Patients With Myelofibrosis
November 17th 2023Abdulraheem Yacoub, MD, reviews the current myelofibrosis treatment landscape including the four approved JAK inhibitors - ruxolitinib, fedratinib, pacritinib, and momelotinib - discussing the clinical trial data and indications for each in first-line and second-line settings.
Watch
Codebreak300: Sotorasib Plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer
November 17th 2023Rachna Shroff, MD, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of Arizona College of Medicine, highlights key data from the Codebreak300 study evaluating if the combination of sotorasib and panitumumab is superior to standard-of-care trifluridine/tipiracil or regorafenib in the setting of chemorefractory metastatic colorectal cancer.
Watch
DLBCL Clinical Trials: Overview of L-MIND and RE-MIND2
November 16th 2023Matthew Lunning, DO, FACP, further explores relapsed/refractory DLBCL treatment strategies and clinical trial findings from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on patient outcomes.
Watch
Monk on KEYNOTE-A18 Data of Pembro/Chemoradiotherapy in Cervical Cancer
November 15th 2023Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Watch
Treatment Goals for Patients With MF
November 15th 2023Anthony Hunter, MD, details the primary goals when treating a typical patient with myelofibrosis, such as improving symptoms like weight loss and fatigue, addressing anemia, and, more recently, striving to extend survival, with treatments like JAK inhibitors showing potential for improving overall survival in patients.
Watch
Myelofibrosis can be categorized as primary (developing de novo) or secondary (arising in patients with pre-existing MPNs), and it further distinguishes between proliferative and cytopenic types, with each type having its unique diagnostic criteria and implications for treatment.
Watch
Clinical Pearls for Community Oncologists Treating Patients With RRMM
November 15th 2023Rafael Fonseca, MD, envisions a future where bispecific antibodies and CAR T-cell therapy, currently used in advanced stages of multiple myeloma treatment, can offer potential cure for patients, and emphasizes the importance of advocating for their broader application in community settings.
Watch